Therapeutic Efficacy of Alpha-RIT Using a 213Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis by Aurélie Derrien et al.
December 2015 | Volume 2 | Article 881
Original research
published: 21 December 2015
doi: 10.3389/fmed.2015.00088
Frontiers in Medicine | www.frontiersin.org
Edited by: 
Jean-Pierre Pouget, 
INSERM, France
Reviewed by: 
Tom A. Bäck, 
University of Gothenburg, Sweden 
Damien Huglo, 
Centre Hospitalier Régional 
Universitaire de Lille, France
*Correspondence:
Michel Chérel  
michel.cherel@univ-nantes.fr
Specialty section: 
This article was submitted to Nuclear 
Medicine, 
a section of the journal 
Frontiers in Medicine
Received: 14 September 2015
Accepted: 30 November 2015
Published: 21 December 2015
Citation: 
Derrien A, Gouard S, Maurel C, 
Gaugler M-H, Bruchertseifer F, 
Morgenstern A, Faivre-Chauvet A, 
Classe J-M and Chérel M (2015) 
Therapeutic Efficacy of Alpha-RIT 
Using a 213Bi-Anti-hCD138 Antibody 
in a Mouse Model of Ovarian 
Peritoneal Carcinomatosis. 
Front. Med. 2:88. 
doi: 10.3389/fmed.2015.00088
Therapeutic efficacy of alpha-riT 
Using a 213Bi-anti-hcD138 antibody 
in a Mouse Model of Ovarian 
Peritoneal carcinomatosis
Aurélie Derrien1,2,3,4 , Sébastien Gouard1,2,3 , Catherine Maurel1,2,3 , Marie-Hélène Gaugler1,2,3 , 
Frank Bruchertseifer5 , Alfred Morgenstern5 , Alain Faivre-Chauvet1,2,3,6 ,  
Jean-Marc Classe1,2,3,7 and Michel Chérel1,2,3,8*
1 Centre Régional de Recherche en Cancérologie Nantes/Angers (CRCNA) UMR892 INSERM, Nantes, France, 2 6299 CNRS, 
Nantes, France, 3 Université de Nantes, Nantes, France, 4 Service de Gynécologie-Obstétrique, CHU de Poitiers, Poitiers, 
France, 5 Institute for Transuranium Elements, European Commission Joint Research Centre, Karlsruhe, Germany, 6 Service 
de Médecine Nucléaire, CHU de Nantes, Nantes, France, 7 Service de Chirurgie Oncologique, Institut de Cancérologie de 
l’Ouest, Saint-Herblain, France, 8 Service de Médecine Nucléaire, Institut de Cancérologie de l’Ouest, Saint-Herblain, France
Purpose: Ovarian peritoneal carcinomatosis is a pathology for which effective cures are 
currently lacking. New research protocols seek to eradicate residual micrometastases 
following cytoreductive surgery by using hyperthermic intraperitoneal chemotherapy 
(HIPEC) or radioimmunotherapy (RIT). This study aims to first develop alpha-RIT using 
an anti-CD138 mAb radiolabeled with an alpha-emitter, bismuth-213 (213Bi-B-B4) and 
HIPEC in a nude mouse model and second to compare and combine these techniques.
Material and methods: A murine model of postoperative ovarian peritoneal carcino-
matosis was established. A pilot group of six mice received an intraperitoneal injection 
of luciferase-tagged SHIN-3 cells and bioluminescence was measured every day.
Cytoreductive surgery was performed at day 14 (n = 4) and 29 (n = 2). Because the 
residual bioluminescence signal measured after surgery was equivalent to that obtained 
3 days after the graft, HIPEC or alpha-RIT treatments were applied 3 days after the 
graft. Ten mice were treated by HIPEC with cisplatine (37.5 mg/mL), 11 with 7.4 MBq 
of 213Bi-B-B4, seven with 11.1 MBq of 213Bi-B-B4, and 10 mice were treated with the 
combined therapy (HIPEC + 7.4 MBq of 213Bi-B-B4). Eleven mice received no treatment. 
Bioluminescence imaging and survival were assessed.
results: Alpha-RIT 7.4 MBq and 11.1 MBq significantly improved survival (p = 0.0303 
and p = 0.0070, respectively), whereas HIPEC and HIPEC + alpha-RIT treatments did 
not significantly ameliorate survival as compared to the control group.
conclusion: Survival was significantly increased by alpha-RIT treatment in mice with 
peritoneal carcinomatosis of ovarian origin; however, HIPEC alone or in combination with 
alpha-RIT had no significant effect.
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inTrODUcTiOn
Epithelial ovarian carcinoma (EOC) is the leading cause of 
mortality linked to gynecological cancer in France with 3357 
deaths in 2006 (1). The first line of treatment is based on a 
combination of maximal cytoreductive surgery and adjuvant 
chemotherapy with platinum salt and taxanes (2). Seventy-five 
percent of patients will experience cancer recurrence, and in 
the absence of complete remission in the initial period, the 
disease will become incurable (3). After initial treatment, the 
prognosis is closely correlated with residual tumor volume (4, 
5). As EOC is mainly confined to the peritoneal cavity in the 
form of peritoneal carcinomatosis, several techniques includ-
ing hyperthermic intraperitoneal chemotherapy (HIPEC) or 
radioimmunotherapy (RIT) are used to target the postoperative 
intraperitoneal residue.
HIPEC involves applying high concentrations of chemother-
apy at cytotoxic temperatures to the intraperitoneal cavity during 
the perioperative cytoreductive period (6). A recent French phase 
III and IV multicenter retrospective cohort study of 566 patients 
treated with HIPEC found mortality and morbidity levels of 
0.8 and 31.3%, respectively, for advanced and recurrent ovarian 
cancer (7). In addition, another multicenter retrospective study 
estimated that overall 4-year survival rates for patients treated 
with HIPEC was 75.6% compared to 19.4% for the control group 
(8), and recently a retrospective observational multi-institutional 
study was conducted showing that HIPEC results in encouraging 
survival rates for patients treated for a first relapse of ovarian 
cancer (9).
RIT is based on a radiopharmaceutical product composed 
of a specific tumor cell vector and a radioisotope. The radiop-
harmaceutical binds to an antigen which is overexpressed by the 
tumor cells and thus ensures selective irradiation. In this context, 
CD138 or Syndecan 1, a transmembrane receptor belonging 
to the heparan sulfate group overexpressed in ovarian tumors 
compared to healthy ovarian tissue, regardless of their status 
of chemoresistance or hormonal sensitivity (10, 11), could be a 
good target candidate. RIT is preferentially used on disseminated 
tumors or small-sized nodules as is the case with peritoneal car-
cinomatosis. A recent review by Tomblyn et al. summarized over 
24 studies of RIT treatment of ovarian cancer in both preclinical 
and clinical studies (phases I–III) (12). The beta-particle emitters 
(iodine-131, rhenium-186, lutetium-177, and yttrium-90) were 
prioritized up until a phase III randomized study by Verheijen 
et al. in 2006 (13) which failed to establish an improvement in 
terms of survival only reduction of intraperitoneal relapses. One 
of the explanations lay in the choice of the radioelement (14). The 
development of alpha-particle emitters has enabled new studies, 
notably those using antibodies or antibody fragments (F(ab′)2) 
labeled with astatine-211, with the results showing good efficacy 
on tumor cell lysis with higher mean doses of radiotherapy 
absorbed (22 Gy) (15).
This study aims to target the residual pathology of ovarian 
peritoneal carcinomatosis by means of a monoclonal humanized 
anti-CD138 antibody radiolabeled with an alpha-particle emitter 
(bismuth-213) and to compare and combine this treatment with 
HIPEC.
MaTerials anD MeThODs
cell line
The SHIN-3 cell line was established from a 56-year-old Japanese 
woman diagnosed with serous cystadenocarcinoma of the ovary 
and was provided by the Medical University of Nara, Japan (16). 
A cDNA sequence coding for Luciferase was obtained from 
the pGL3 vector (Promega). The fragment was subcloned into 
the retroviral vector pMX (17) and retroviral transduction of 
SHIN-3 cells was performed by standard molecular methods. 
SHIN-3-Luc+ cells were grown in RPMI 1640 medium (Sigma-
Aldrich) supplemented with 10% heat-inactivated fetal calf 
serum (PAA), 2 mM glutamine (Invitrogen), 100 U/mL penicil-
lin (Invitrogen), and 100 μg/mL streptomycin (Invitrogen) at 
37°C, 5% CO2, and 100% humidity. The doubling time of SHIN-
3-Luc+ cells was 29 h.
cellular expression of cD138 and cea by 
Flow cytometry
To measure cellular expression of CD138 and CEA on SHIN-
3-Luc+ cells, 200,000 cells were incubated for 1  h at 4°C with 
anti-CD138 (B-B4, Diaclone), anti-CEA (T84.66) antibodies or 
with isotype control mouse IgG1 (BD Biosciences) at 10 μg/mL, 
followed by a secondary phycoerythrin conjugated anti-rat anti-
body (Jackson Immuno Research) for 1 h. Analysis was carried 
out using a FACSArray flow cytometer (Becton Dickinson). Data 
analysis was conducted using Flowjo software.
Ovarian Peritoneal carcinomatosis Mouse 
Model
NMRI-nu (nu/nu) mice were purchased from Janvier and housed 
under conventional conditions at the UTE animal facility (SFR 
François Bonamy, IRS-UN, University of Nantes, license number: 
B-44-278). Experiments were approved by the local veterinary 
committee (License number: CEEA.2013.2).
Mice were 7–10 weeks old at the time of experiments and were 
grafted using intraperitoneal injection with 5 × 106 SHIN-3-Luc+ 
cells in 0.3 mL of phosphate buffer saline.
Monitoring of Ovarian Peritoneal 
carcinomatosis by Bioluminescence
One hundred microliters of luciferin solution (12 mg/mL) was 
injected intraperitoneally 5 min before the acquisition of images 
(17). The mice were then anesthetized in an airtight container 
containing 3.5% of isoflurane (Abbott Laboratories) and isoflu-
rane was maintained using a nose cone delivery system when 
passing under the “photon Imager” camera (Biospace Lab). 
Images were taken for each mouse for 1 min on both sides (in 
prone and supine positions). All images were analyzed (soft-
ware M3viewer 2.2, Biospace Lab) while determining a specific 
region of interest (ROI) encompassing the entire surface of the 
mouse (except tail). For each mouse, each time point was the 
sum of the photon counts obtained in both prone and supine 
positions.
FigUre 1 | Peritoneal carcinomatosis index (Pci) in mice. Exploration of the 13 standard regions of the abdominal cavity was carried out using magnifiers 
according to the descriptions of tumor damage by PCI scoring adapted from those of Klaver et al. (18) and Sugarbaker (6).
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cytoreductive surgery and 
Postoperative residual Volume 
Determination
Cytoreductive surgery was performed 14 days (n = 4) and 29 days 
(n = 2) after injection of 5 × 106 SHIN-3-Luc+ cells. Mice were 
anesthetized following intraperitoneal injection of 100 μL/10 g 
anesthetic solution (consisting of 1 mL ketamine at 100 mg/mL, 
Panpharma; 0.5  mL xylazine at 20  mg/mL, Bayer; and 8.5  mL 
PBS). A midline laparotomy was performed. Thorough explora-
tion of the abdominal cavity was carried out using magnifiers for 
the 13 standard regions defined by Sugarbaker (6) and adapted to 
rodents by Klaver et al. (18). For the present study, descriptions of 
tumor damage by Peritoneal Carcinomatosis Index (PCI) scores 
are summarized in Figure  1. Scores from 0 to 3 were defined 
for each region (0): no macroscopic tumor; (1): lesion from 1 to 
2 mm, 1 to 2 sites; (2): lesion from 2 to 4 mm, 1 to 2 sites; and (3): 
lesion over 4 mm or more than 10 sites. The total PCI score was 
calculated as the sum of the score for each region and could thus 
range from 0 to 39. All observed nodules were resected using an 
electric scalpel blade. At the end of the procedure, the quality of 
the exeresis was described and classified using a “completeness 
of cytoreduction” (CC) score adapted from Sugarbaker (6) and 
Klaver et  al. (18): CC0: absence of macroscopic residue, CC1: 
tumoral residue below 2.5 mm, and CC2: tumoral residue above 
2.5 mm. The lining was sutured along two planes. Postoperative 
analgesia was provided by i.p. injection of 0.20 μL buprenorphine 
at 0.3  mg/mL (Axience), repeated after 12  h, followed by oral 
administration of anti-inflammatory drugs (Ibuprofen, 7.5 mg/
kg, Wyeth).
Bioluminescent imaging was carried out after cytoreductive 
surgery while the animals were still under anesthesia to evaluate 
the correlation between postoperative residual tumor volume and 
bioluminescence signal.
Determination of the Optimal Time of 
Treatment after engraftment
Eleven mice were grafted with 5 × 106 SHIN-3-Luc+ cells (control 
mice). Bioluminescence imaging was performed 1, 2, 3, 7, 11, 14, 
18, and 21 days after engraftment. To determine the time after 
engraftment mimicking the postoperative residual tumor vol-
ume, i.e., time of HIPEC/alpha-RIT treatment, bioluminescence 
signals were compared to those obtained from the four and 
two mice which had cytoreductive surgery 14 and 29 days after 
engraftment, respectively.
hiPec
Mice were anesthetized in an induction chamber and maintained 
using a mask (isoflurane 1.5%). Mice were placed on a heat pad 
and a 1–2-cm midline incision was made. The instillation tube 
and a multiperforated suction appliance were inserted inside 
the abdomen and cisplatin was administered (Generic Merck, 
37.5 mg/mL or 75 mg/m2). The Erlenmeyer flask containing the 
cisplatin was placed in a water bath heated to 49°C, and admin-
istration was achieved using a peristaltic pump (3 mL/min). The 
temperature of the intraperitoneal solution was 39°C as previ-
ously described by Muller et al. (19) and was regularly checked 
using a thermal probe. The tubes were often repositioned in the 
abdominal cavity and the abdomen was regularly massaged. After 
60  min, the lining was sutured along two planes using Vicryl® 
4-0. The animal recovered consciousness under a heat lamp and 
postoperative analgesia was provided as previously described.
B-B4 radiolabeling with Bismuth-213 and 
In vivo alpha-riT
B-B4 was conjugated with the chelating agent CHX-A"-DTPA 
(Macrocyclics) according to the protocol described by Supiot 
et al. (20). The bismuth-213 was eluted from the actinium-225/
bismuth-213 generator using a solution composed of 500 μL 
of 0.2 M NaI and 500  μL of 0.2 N HCl (21). One hundred 
micrograms of antibody, along with 195  μL of 4 M NaOAc 
buffer solution and 75 μL of 20% ascorbic acid were added. 
After 10  min at 37°C, the antibody was purified of free 
bismuth-213 on a PD-10 desalting column (GE Healthcare) 
in 0.3  mL PBS fractions. The fractions with highest activity 
were combined and the total activity was assessed using a NaI 
detector (X-ray test). Next, 213Bi-B-B4 was filtered through a 
0.2 μm filter (Whatman, Anotop 10) before being injected i.p. 
FigUre 2 | cD138 and cea expression by flow cytometry. The 
SHIN-3-Luc+ cells were incubated in the presence of a saturating dose of 
anti-CD138 (IgG1 mouse, B-B4, black), anti-CEA (IgG1 mouse, T84.66; 
gray), or an isotype control antibody (IgG1 mouse, gray line). One 
representative experiment (out of 3 independent experiments) is shown.
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(from 350 to 430 μL). The specific activity after filtration was 
0.48 ± 0.07 MBq/μg of mAb.
Three days after engraftment, for alpha-RIT, 7.4  MBq or 
11.1 MBq of 213Bi-B–B4 were injected and for the HIPEC + alpha-
RIT group, 7.4 MBq of 213Bi-B–B4 were injected immediately after 
HIPEC surgery, either during or after recovery.
animal Monitoring
Every week, the mice were weighed, clinically assessed and biolu-
minescence imaging was carried out. The animals were sacrificed 
if they met the ethical conditions of euthanasia; signs of abnormal 
behavior (difficulty moving and feeding), excessive weight loss, 
major ascites. Next, an autopsy was performed on all mice. For 
each animal the tumor volume was assessed and assigned a PCI 
score. The endpoint of the study was set at 90 days. Blood samples 
were collected into tubes containing 5% EDTA. Platelets, white, 
and red blood cells were counted by a quantitative automated 
hematology analyzer (Melet-Schloesing).
statistical analysis
Statistical analysis was conducted via GraphPad Prism software 
(GraphPad Software Inc., San Diego CA). Analysis of the differ-
ent groups of treated mice at the end of the study was conducted 
using a two-way repeated measures variance analysis (two-way 
ANOVA). Corrections for the multiple groups were carried 
out using Bonferoni tests. Comparison of postoperative aver-
age signals of bioluminescence was obtained using a Student’s 
t-test with 4 degrees of freedom. Finally, survival was examined 
by means of a Kaplan–Meier survival curve and log-rank test 
analysis.
resUlTs
expression of cD138 and cea by shin-3-
luc+ cells
The expression of CD138 by SHIN-3-Luc+ cells was compared 
to that of CEA which has previously been used as a RIT target 
(22). The data relating to flow cytometry analysis of SHIN-
3-Luc+ cells (Figure  2) show that CD138 expression was 
10 times higher than that of CEA (MFI of 26,825 and 2,530, 
respectively).
Ovarian Peritoneal carcinomatosis Model
Female nude mice were injected with 5  ×  106 SHIN-3-Luc+ 
cells. The first ascitic fluid was apparent on day 27 after grafting. 
The distribution of nodules was very heterogeneous and dis-
seminated as shown in Figures 3A,B, closely mimicking human 
ovarian peritoneal carcinomatosis. A similar heterogeneity and 
dissemination were observed from the bioluminescence signal 
acquisition (Figure 3C).
Determining the correspondence Between 
Postoperative residual Tumor Volume and 
Bioluminescence signal
Currently, therapies such as HIPEC or RIT are considered as adju-
vant therapies applied immediately before or after cytoreductive 
surgery. In order to treat animals in a comparable manner while 
avoiding cytoreductive surgery, the postoperative residual tumor 
volume was assessed by bioluminescence imaging on 6 mice 
grafted with 5 × 106 SHIN-3-Luc+ cells. Four mice with a total 
PCI score ranging from 2 to 5 (2, 3, 3, and 5) had cytoreductive 
surgery on day 14. After the procedure, the CC was between 0 and 
1 (0, 0, 1, and 1). Two other mice with a total PCI score of 6 and 
11, respectively, had cytoreductive surgery on day 29. Both mice 
had a CC score of 1 after the surgery.
Bioluminescence signals obtained postoperatively from these 
mice operated 14 and 29 days after engraftment were, respectively, 
4.9 × 105 ± 3.3 × 105 counts (n = 4) and 3.7 × 105 ± 1.7 × 105 counts 
(n =  2). The comparison of these two means using a Student’s 
t-test with 4 degrees of freedom did not show any significant 
difference (p < 0.005). Hence, a postoperative bioluminescence 
signal was established at 4.3 × 105 counts accumulated per mouse 
corresponding to postoperative residual tumor volume (i.e., CC 
between 0 and 1).
Determining by Bioluminescence the Day 
after engraftment Mimicking 
Postoperative residual Tumor Volume
Bioluminescence was measured for 11 mice from 1 to 21  days 
after engraftment. Figure 4 shows the progression of the disease 
expressed as the evolution of the bioluminescence signals accord-
ing to the day after the engraftment. Postoperative biolumines-
cence signals of 4.9 × 105 counts, 3.7 × 105 counts and 4.3 × 105 
counts reported on the y-axis of Figure 4 (see insert), correspond 
FigUre 3 | shin-3-luc+ ovarian peritoneal carcinomatosis model in nude mice. (a) Shows the frequency in the localization of intra-abdominal tumoral 
damage in nude mice after grafting with 5 × 106 SHIN-3-Luc+ cells. These evaluations were carried out on all mice during cytoreductive surgery or following death. 
(B) Is a photograph illustrating the distribution of tumoral lesions in the abdominal cavity in a nude mouse with a graft of 5 × 106 SHIN-3-Luc+ cells after sacrifice. 
Circles highlight visible tumor lesions. (c) Is a photograph illustrating the bioluminescence signal measured with the photon Imager.
FigUre 4 | Progression of the bioluminescence signal according to 
the day after engraftment. Bioluminescence signals were measured for 11 
mice up until 21 days after engraftment. The insert focuses on the first 4 days 
after engraftment. The day after engraftment mimicking the postoperative 
residual tumor volume, i.e., the disease status after cytoreductive surgery, 
was determined by reporting the postoperative bioluminescence signals on 
the y-axis to against the corresponding day on the x-axis.
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on the x-axis to an interval of one day, just before day 3 and day 4, 
after engraftment. Day 3 was defined as the day after engraftment 
mimicking the postoperative residual tumor volume, i.e., the 
disease status after cytoreductive surgery.
To verify the tumor status 3 days after engraftment, five mice 
grafted with 5 × 106 SHIN-3-Luc+ cells were sacrificed after bio-
luminescence imaging 3 days later (3.9 × 105 ± 1.6 × 105 counts). 
As shown in Table 1, the total PCI score for each mouse was 3, 
3, 1, 2, and 1. All tumor lesions were less than 2 mm as the PCI 
score for each region was never >1. Thus, the tumor status of each 
mouse at day 3 was equivalent to a CC score <1.
Treatment of residual Tumor Volume
In two independent experiments, 49 mice were randomly assigned 
to the different treatment groups which were initiated on day 3 
after the graft. A first experiment included control (n = 6), HIPEC 
only (n = 5), alpha-RIT 7.4 MBq (n = 6), and HIPEC + alpha-
RIT 7.4 MBq (n = 5) groups. The second experiment included 
control (n = 5), HIPEC only (n = 5), alpha-RIT 7.4 MBq (n = 5), 
alpha-RIT 11.1 MBq (n = 7), and HIPEC + alpha-RIT 7.4 MBq 
(n = 5) groups. During HIPEC, the intraperitoneal temperatures 
of both the HIPEC and the HIPEC + alpha-RIT groups remained 
at a stable average temperature of 39°C. Two intraoperative deaths 
were observed.
clinical results
The mice receiving HIPEC treatment alone had a weight loss of 
2 g at day 4 after the treatment, equal to that of the alpha-RIT 
groups, while those from the HIPEC + alpha-RIT group experi-
enced a weight loss of 4 g (Figure 5). At day 7, the mice treated 
with alpha-RIT recovered their initial weights. On the contrary, 
the weights of HIPEC and HIPEC + alpha-RIT mice were never 
restored (Figure 5).
Bioluminescence results and Pci-scoring
Figure 6 shows changes in the bioluminescence signal for each 
mouse in relation to the treatment received. These results show 
that the bioluminescence signal was much weaker for the groups 
having received alpha-RIT. Only the curves relating to HIPEC 
come close to matching those of the mice receiving no treatment.
At sacrifice, the abdominal cavity of the mice was explored 
to establish the PCI score. The average PCI score was compared 
to the average maximal bioluminescence signal, with results 
showing a correlation of the two parameters. Indeed, for the 
control group an average PCI of 32.4 was found for a maximal 
average bioluminescence signal of 2.7 × 107 photon counts. For 
the HIPEC group only a PCI average of 26.6 with an average 
FigUre 5 | Weight monitoring of mice after treatment. This figure 
illustrates the weight changes for each group (control n = 6, HIPEC n = 5, 
alpha-RIT 7.4 MBq n = 6, alpha-RIT 11.1 MBq n = 7, and HIPEC + alpha-
RIT 7.4 MBq n = 5) according to the day after engraftment.
TaBle 1 | Pci scoring 3 days after engraftment in the 13 standard regions (n = 5).
region number
0 1 2 3 4 5 6 7 8 9 10 11 12 Total Pci
Mouse 1 0 0 0 1 0 0 1 0 1 0 0 0 0 3
Mouse 2 0 0 0 0 0 0 0 1 1 0 0 0 1 3
Mouse 3 0 0 1 0 0 0 0 0 0 0 0 0 0 1
Mouse 4 0 0 0 1 0 0 0 1 0 0 0 0 0 2
Mouse 5 0 0 0 1 0 0 0 0 0 0 0 0 0 1
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maximal bioluminescence signal of 2.2  ×  107 counts, for the 
combined HIPEC + alpha-RIT group a PCI average of 28.5 for an 
average maximal bioluminescence signal of 1.2 × 107 counts, and 
for the alpha-RIT group at 7.4 MBq an average PCI of 10.6 with 
a maximal average bioluminescence signal of 0.45 × 107counts.
Toxicity
In terms of blood toxicity, Figure 7 shows a transient but none-
theless insignificant reduction in platelets and white blood cells 
for all treatments. For HIPEC alone, a substantial reduction in 
red blood cells was highlighted 51 days after treatment with no 
hemorrhage being observed.
survival
The survival curves are shown in Figure  8. The first deaths 
occurred intraoperatively for the mice from the HIPEC + alpha-
RIT group and the HIPEC group (two deaths on the day of the 
procedure). Similarly, the two groups receiving HIPEC experi-
enced the most premature deaths (two on day 8 after the graft 
and one on day 13 after the graft), without evident causes being 
established via autopsies. Median survival was 68  days for the 
control group, 75.5 days for the combined HIPEC + alpha-RIT 
group and 37.5 days for the HIPEC group. Median survival rates 
for the groups having received RIT alone cannot be calculated, 
given that over 50% of the mice were still alive at the end of the 
experiment. Indeed, at 90  days, seven mice out of 11 (63.6%) 
were still alive in the group receiving alpha-RIT 7.4  MBq and 
five out of seven (71.4%) in the group with alpha-RIT 11.1 MBq. 
In this last group, one mouse was sacrificed due to major weight 
loss and the necropsy could only establish two small millimeter-
sized tumoral nodules. As compared to the control group curve, 
HIPEC and HIPEC + alpha-RIT curves were not significantly dif-
ferent whereas alpha-RIT 7.4 MBq and alpha-RIT 11.1 MBq were 
significantly different (p = 0.0303 and p = 0.0070, respectively).
DiscUssiOn
The present preclinical study is the first to compare and combine 
HIPEC and alpha-RIT for the treatment of ovarian peritoneal 
carcinomatosis in a model mimicking postoperative residual 
tumor illness. Alpha-RIT, combining anti-CD138, and bis-
muth-213 showed a substantial increase in overall survival in 
correlation with low bioluminescence signals. However, HIPEC 
did not show significant improvements in terms of survival but 
did show a reduction in median survival and disease progres-
sion measured by bioluminescence, similar to the control group. 
Finally, a combination of both therapies did not show significant 
improvements in overall survival. With an uncertain prognosis 
(3) and based on residual tumor volume after surgery (4, 5), 
the development of innovative therapies in EOC is required for 
reliable and reproducible preclinical models. Our model based 
on SHIN-3 cells offers the advantage of rapidly establishing 
peritoneal carcinoma disease (Figure 3) that is identical to that 
found in advanced ovarian cancer.
Cytoreductive surgery plays a key role in the treatment of 
EOC, and disease prognosis depends on the degree of its suc-
cess (5). The possibility of applying this surgery to preclinical 
models on animals has been demonstrated, notably with rats for 
colon cancer (18, 23) but also with mice (24). Nevertheless, the 
teams studying therapies targeting postoperative residual tumor 
volume seek to amend surgery, and administer their therapies 
at an early stage of the graft, often day 1 or day 2, under the 
assumption that the tumor volume must be the same at day 1 and 
day 2 (24), without taking into account the viability of the graft at 
FigUre 6 | changes in bioluminescence signal in relation to treatment received. This figure shows changes in bioluminescence signal for each group 
treated (control n = 11, HIPEC n = 7, alpha-RIT 7.4 MBq n = 11, alpha-RIT 11.1 MBq n = 7, and HIPEC + alpha-RIT 7.4 MBq n = 10) as a function of time (days 
after engraftment). For each mouse and each time point, the sum of the bioluminescence signal obtained in both the prone and the supine positions is represented.
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this early stage. Our cytoreductive surgery model performed on 
6 mice has enabled us to determine the correspondence between 
the bioluminescence signal obtained immediately after surgery 
and the one obtained after engraftment. We therefore decided 
to treat the animals on day 3 in order to be as close as possible 
to the postoperative state of the tumor. Finally, cytoreductive 
surgery was performed in the context of PCI scoring between 2 
and 11, corresponding to advanced phases of disease, with the 
results of cytoreduction (CC 0–1) similar to those obtained in 
the clinic (7).
RIT has been used for EOC treatment since the 1980s (25) 
with constant clinical inefficiency of RIT using beta particles 
(13). However, the efficacy of alpha particle vectorization has 
been demonstrated in preclinical ovarian cancer models (15), 
subsequently leading to a phase I clinical trial (26). In our study, 
we used bismuth-213 as an alpha-particle emitter. Although 
the half-life of bismuth-213 (45 min) seems theoretically more 
advantageous than that of astatine-211 (7.2  h) with the aim of 
restricting intraperitoneal cavity activity, a study by Gustafsson 
has shown similar effects between two alpha particle emitters 
FigUre 7 | Measurement of blood cell counts according to treatment groups. This figure shows the average changes in red blood cell levels, leukocytes, 
and platelets as a function of time (days after engraftment) and treatment group.
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(27). The activities of bismuth-213 used in our study (7.4 and 
11.1 MBq) did not result in acute blood toxicity and are consistent 
with a study by Song et al. (28) which showed, for an antibody 
injected by i.p., a MTD of 35 MBq for a nude mouse of 30g. In 
the same manner, HIPEC, developed to improve the benefits of 
intraperitoneal chemotherapy while amending inflammatory 
procedures, may be worthwhile as a direct application of intra-
operative RIT on difficult or partial areas of resection so as to 
target residual disease.
CD138 or syndecan-1 belongs to the heparan sulfate pro-
teoglycan family and is often targeted during RIT treatments. 
Two studies have examined the expression of CD138 in ovarian 
cancer: the first (10) revealed the presence of CD138 in benign 
tumors and the borderline of the ovary, and in adenocarcinomas 
(present in epithelial and stromal cells), while not being expressed 
by healthy ovarian tissue. The second study showed higher CD138 
expression in all cancer types compared to healthy ovarian tissue, 
without any correlation in terms of chemoresistance or exposure 
to estrogens (11). Therefore, we considered CD138 as a potential 
innovative target antigen for the treatment of ovarian cancer by 
RIT, in the same way as other emerging targets such as Her2 (29) 
or VEGF (30). This choice was strengthened by the results that 
we obtained in this study on CD138 expression and RIT. CD138-
targeted alpha-RIT results in a marked difference in terms of 
bioluminescence signals (Figure  6). Furthermore, as shown in 
Figure  8, we observed a significant increase in survival (63.6 
and 71.4%, respectively) at 90 days for the alpha-RIT 7.4 MBq 
(p  =  0.0303) and alpha-RIT 11.1  MBq (p  =  0.0070) groups 
compared with 10% for the untreated mice. In addition, the mice 
treated with alpha-RIT experienced lower weight loss than the 
other groups, and a markedly lower tumor volume at necropsy 
(PCI average of 10.6).
The HIPEC technique used in this study was designed to 
reproduce as faithfully as possible the technique used on humans 
with EOC, consisting of a semiopen procedure with cisplatin 
perfusion at 3  mL/min (24). In France, cisplatin is the most 
frequent chemotherapeutic product used in ovarian HIPEC (7). 
Doses >80 mg/m2 result in renal failure (31). In this study, the 
concentration of cisplatin was 75 mg/m2 or 2 mg/kg. The upper 
intraperitoneal temperature limit tolerated was 40°C, as bowel 
lesions can occur in rodents at higher temperatures (32). In a pre-
liminary study, we demonstrated that using temperatures above 
40°C on SHIN-3 cells required an increase in the concentration of 
cisplatin in order to obtain a similar cytotoxic effect (19).
In the present study, the group receiving HIPEC alone did 
not show any differences in terms of bioluminescence signal 
(Figure 6) or overall survival (Figure 8) compared to the control 
group. Median survival of these animals is even lower than that of 
the control group: 34 versus 68 days. There is a paucity of mouse 
studies evaluating cisplatin-based HIPEC in EOC. A study on 
the impact of the addition of sodium arsenite and variations in 
temperature in cisplatin HIPEC did not include survival as an 
assessment criterion and all the animals were euthanized from 
day 1 (24). In preclinical studies on colon cancer, HIPEC is 
associated with intense toxicity and a general worsening state, 
including lethargy, substantial weight loss, and bacterial trans-
locations (33). However, we did not observe intense toxicity in 
our group of animals treated with HIPEC. Indeed, on average, 
initial weight loss of 2 g was observed, which was equivalent to 
the alpha-RIT-treated group, and below that of the combined 
FigUre 8 | survival rates according to treatment groups. This figure 
shows the Kaplan–Meier survival curves of mice as a function of treatment by 
day 3, and according to the number of days.
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HIPEC  +  alpha-RIT-treated group. Similarly, blood sample 
analysis did not indicate greater toxicity in this group. In 2010, 
Klaver et al. compared the survival of cancer bearing rats treated 
by cytoreductive surgery alone or combined cytoreductive 
surgery and HIPEC, with greater survival for animals treated by 
HIPEC surgery (18). Next we combined HIPEC and alpha-RIT 
for the first time in an animal model. The alpha-RIT injection was 
carried out immediately after HIPEC, and only one mouse had to 
be reinjected with alpha-RIT due to leakage of the radiolabeled 
vector. While the bioluminescence curve appeared different to the 
control group (Figure 6), no significant difference was noted in 
terms of survival (Figure 8). Examination of the survival curve of 
the HIPEC + alpha-RIT group, showed early deaths potentially 
due to the toxicity of the combined treatments. This hypothesis is 
supported by the higher initial weight loss in this group (4 g), but 
did not correlate with toxicity as measured by blood sample analy-
sis (Figure 7). Second, this group displayed fewer deaths and mice 
appeared similar to those of the groups treated with alpha-RIT. 
Currently, no study has associated these two treatments. Only one 
Dutch team has compared them in two separate studies. The first 
used rats with peritoneal carcinoma of colorectal origin treated 
by HIPEC or alpha-RIT after cytoreductive surgery was focused 
on animal survival (34). A second study, using the same model, 
focused on the impact of these treatments on abdominal healing 
after surgery (35). In the first study, concerning survival (34), the 
results are in favor of alpha-RIT, with a non-significant increase 
in survival for the HIPEC group compared to the control group.
cOnclUsiOn
The present study indicates the potential therapeutic effect of 
alpha-RIT in EOC. It demonstrates that the use of postoperative 
alpha-RIT in a context mimicking the residual tumor after 
cytoreductive surgery dramatically increased survival rates of 
mice with peritoneal carcinomatosis of ovarian origin. Under 
the same conditions, HIPEC treatment alone or combined 
HIPEC +  alpha-RIT did not offer significant improvements to 
survival rates. We believe alpha-RIT provides a potentially inter-
esting alternative adjuvant treatment along with cytoreductive 
surgery in the treatment of ovarian cancer. Furthermore, our 
study has extended the scope of available target antigens for RIT, 
showing that CD138 can be used effectively to target peritoneal 
carcinoma cells.
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